Selected Posters and Abstracts
Fosamprenavir (Lexiva)
Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral naive HIV-1 infected patients: 24-week results from COL103952 (ALERT)
K Smith and others.
Fosamprenavir/ritonavir (FPV/r): decrease of liver enzymes in patients co-infected with hepatitis C
C Koegl and others.
Success of an induction-maintenance strategy using boosted fosamprenavir plus zidovudine and lamivudine for treating HIV-1 infected drug-naive subjects
P Di Vincenzo and others.
Fosamprenavir boosted with a single 100 mg capsule of ritonavir as part of a once daily first line regimen in naive patients
SDe Wit and others.
Sustained virologic and immunologic response over 180 weeks in antiretroviral therapy (ART)-naïve subjects receiving fosamprenavir/ritonavir (FPV/r) QD
N Bellos and others. 
Efficacy and safety of once-daily boosted fosamprenavir/ritonavir (FPV/r) with abacavir (ABC)/lamivudine (3TC) fixed dose combination in antiretroviral naive HIV-1 infected patients: 24-week results from COL100758|
C Hicks and others.
A clinically validated mutation score for resistance to fosamprenavir/ritonavir
B Masquelier and others. 

Dosing fosamprenavir in cirrhotic patients: possible role of TDM
F Gatti and others.


<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva

Norvir
Prezista

Reyataz
Viracept


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen


non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor

Sustiva
Viramune

Entry Inhibitors
Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada